CN100382783C - Psoralea drip pill an dits preparation method - Google Patents
Psoralea drip pill an dits preparation method Download PDFInfo
- Publication number
- CN100382783C CN100382783C CNB2005100634686A CN200510063468A CN100382783C CN 100382783 C CN100382783 C CN 100382783C CN B2005100634686 A CNB2005100634686 A CN B2005100634686A CN 200510063468 A CN200510063468 A CN 200510063468A CN 100382783 C CN100382783 C CN 100382783C
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- fructus psoraleae
- drug extract
- substrate
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a medicine composition used for the treatment of vitiligo, psoriasis and other diseases, which has the functions of warming the kidney and strengthening body resistance. The present invention has the purpose of complementing the deficiency of existing oral medicine preparations used for the treatment of the diseases, providing fructus psoraleae dripping pills which is an oral medicine composition preparation having high bioavailability, quick medicine release, rapid effect, low price and no pollution during production. The fructus psoraleae dripping pills of the present invention are prepared from the raw material of fructus psoraleae which is a Chinese medicine, and medicinal carriers serving as matrixes.
Description
Technical field
The present invention relates to a kind of the kidney warming centralizing function that has, be used for the treatment of the pharmaceutical composition of diseases such as vitiligo, psoriasis, is raw material with the Chinese medicine Fructus Psoraleae particularly, a kind of drug composition oral preparation that is prepared from the pharmaceutically suitable carrier as substrate.
Background technology
According to the drug standard WS promulgated by the ministries or commissions of the Central Government of country
3The Fructus Psoraleae injection that prescription that provides among-the B-3226-98 and extraction process are prepared from, be a kind of pure Chinese medicine that is used for the treatment of diseases such as vitiligo, psoriasis, through clinical verification for many years, steady quality, determined curative effect is the common drug that is used for the treatment of above-mentioned disease clinically with family.
Below be drug standard WS
3Prescription that provides among-the B-3226-98 and extraction process:
Prescription: Fructus Psoraleae coarse powder 500g;
Method for making: get Fructus Psoraleae coarse powder 500g,, make solvent with 75% ethanol according to percolation (appendix IO) under fluid extract and the extractum item, flood after 48 hours slowly percolation, collect percolate 2500ml, filter, at 60 ℃ of decompression recycling ethanols, and be concentrated into the thick paste that relative density is 1.05～1.10 (20 ℃), be diluted to 1000ml with 0.85% sodium chloride solution, stir, left standstill 12 hours, draw supernatant, add 2g polyoxyethylene sorbitan monoleate and 3g active carbon, stir evenly, 100 ℃ of heating 30 minutes, put and be chilled to room temperature, transfer pH value to 3.0 with dilute hydrochloric acid,, filter 4 ℃ of cold preservations 24 hours, transfer pH value to 7.0 with 10% sodium hydroxide solution, add 0.85% sodium chloride solution to 1000ml, filter embedding, sterilization, promptly.
Function cures mainly: the kidney warming is set upright.Be used to control news vitiligo, psoriasis (psoriasis).
Owing to be subjected to the influence of existing injection technology of preparing restriction and Chinese medicinal ingredients complexity, Chinese medicine injection often is easy to generate acute allergic reaction or untoward reaction, it is big also to exist operation easier simultaneously, the patient suffering is big, make and the medical treatment cost height, transportation stores inconvenience, and patient economy burden is heavy, shortcomings such as unsuitable family use.
In addition, owing to reasons such as technologies of preparing, the oral formulations of most drug exists all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.Simultaneously, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.Therefore, be necessary to seek the peroral dosage form of better Flos Carthami medicine to satisfy the needs that clinical treatment and family use.
Summary of the invention
Purpose of the present invention, be to replenish the existing deficiency that is used for the treatment of the oral drug preparation of diseases such as vitiligo, psoriasis, a kind of bioavailability height is provided, release fast, quick produce effects, toxic and side effects is little, and manufacturing and medical treatment cost are low, low price, the oral Fructus Psoraleae drop pill that is suitable for family to use.Fructus Psoraleae drop pill involved in the present invention is a raw material with the Chinese medicine Fructus Psoraleae, is prepared from the pharmaceutically suitable carrier as substrate.Be prepared by the following technical solutions, can obtain Fructus Psoraleae drop pill involved in the present invention:
[preparation method]
1. the preparation of drug extract: get Fructus Psoraleae coarse powder 500g, according to percolation under 2000 editions Pharmacopoeia of People's Republic of China appendix IO fluid extracts and the extractum item, make solvent with 75% ethanol, flood after 48 hours slowly percolation, collect percolate 2500ml, filter, at 60 ℃, being decompressed to and being concentrated into relative density under the 0.1MPa condition is 1.05～1.15 thick paste, or continues to make drying under the same conditions, be ground into dry powder, promptly get drug extract thick paste or dry powder;
2. substrate: Polyethylene Glycol
(1000～20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, beta-schardinger dextrin-, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. according to the given ratio of prescription, accurately take by weighing drug extract and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～90) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. when treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively and reaching desired state of temperature, fused solution and/or the emulsion and/or the suspension that will contain drug extract and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent, condensing agent can be any one in liquid paraffin, methyl-silicone oil, the vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.
Beneficial effect
According to the drug standard WS promulgated by the ministries or commissions of the Central Government of country
3The Fructus Psoraleae injection that prescription that provides among-the B-3226-98 and extraction process are prepared from, be a kind of pure Chinese medicine that is used for the treatment of diseases such as vitiligo, psoriasis, through clinical verification for many years, steady quality, determined curative effect is the common drug that is used for the treatment of above-mentioned disease clinically with family.
Owing to be subjected to the influence of existing injection technology of preparing restriction and Chinese medicinal ingredients complexity, Chinese medicine injection often is easy to generate acute allergic reaction or untoward reaction, it is big also to exist operation easier simultaneously, the patient suffering is big, make and the medical treatment cost height, transportation stores inconvenience, and patient economy burden is heavy, shortcomings such as unsuitable family use.
The oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.
In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Fructus Psoraleae drop pill involved in the present invention is compared with Fructus Psoraleae injection, and following beneficial effect is arranged:
1. Fructus Psoraleae drop pill involved in the present invention; utilize surfactant to be substrate; make solid dispersion with extractum that contains the Fructus Psoraleae active constituents of medicine or dry powder; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases, and substrate is hydrophilic, and medicine is had wetting action; can make that medicine is rapidly molten to loose into microgranule or solution, thereby make the dissolving of medicine and absorb and accelerate.Thereby improved bioavailability, brought into play efficient, quick-acting effects etc.
Compare with the administering mode of traditional oral formulations, exist essential distinction.Drop pill with the solid dispersion technology preparation can adopt oral and sublingual administration, and effective ingredient is fully contacted with mucomembranous surface, absorbs by mucomembranous epithelial cell, directly enters blood circulation.Owing to directly enter blood circulation without gastrointestinal tract and liver, avoided first pass effect effectively, also avoided gastrointestinal irritation, thereby it is rapid to have an onset, bioavailability height, characteristics such as side effect is little, and medication is convenient.
Chinese patent medicine injection series products is because of producing and basic research seriously lags behind, and the standardization issue of medicine never is resolved.The Chinese crude drug raw material itself is exactly a miscellaneous complex of chemical constituent, also there is not a kind of effective quality control method can reflect the quality and the difference thereof of product comprehensively, comprehensively, truly so far, and can carry out the quality control of production overall process effectively, cause the drug quality instability.The untoward reaction of Chinese medicine at present happens occasionally, but can't fundamentally understand fully to be due to which kind of composition, therefore can not in time make and deal with the aftermath of remedial measure targetedly, stay hidden danger for the hospital clinical medication.Injection manufacturing in addition, cost of transportation height use inconvenience, and this had both increased the weight of patient economy burden, have increased the misery of using again.Compare with Flos Carthami injection, the oral administration dripping pill agent has avoided medicine directly into blood, can reduce acute toxic and side effects and anaphylactoid generation effectively, and is safe and convenient to use, and effect is lasting, applied range; Manufacturing and medical treatment cost reduce greatly simultaneously, have effectively alleviated patient's financial burden, and have stored, transport, carry and use all more convenient.
2. Fructus Psoraleae drop pill involved in the present invention contacts promptly with saliva and to dissolve rapidly, and is absorbed by oral mucosa, and is not only rapid-action, and the influence of not taken food, and promptly all can containing take after meal ante cibum.
3. Fructus Psoraleae drop pill involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. Fructus Psoraleae drop pill involved in the present invention, stable in properties than injection, has the anaphylaxis of not being prone to, and side effect is little, also has advantages such as high bioavailability simultaneously.
5. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
6. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind, and compares with oral liquid, and the dosage of drop pill is accurate, thereby makes the patient take metering control easily.
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of Fructus Psoraleae drop pill of the present invention.
First group: the test of single-matrix
1. raw material: it is standby to make the dry powder that contains Chinese medicine Fructus Psoraleae active pharmaceutical ingredient in advance according to preparation method 1;
2. substrate: Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, beta-schardinger dextrin-, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac etc.;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the Fructus Psoraleae drop pill of different size.
[result of the test]
Test 1: for observe drug extract and different substrates when 1: 1 the proportioning prepared Fructus Psoraleae drop pill in qualitative difference, according to 1: 1 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol 1
0000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, beta-schardinger dextrin-, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 1.
Test 2: for observe drug extract and different substrates when 1: 3 the proportioning prepared Fructus Psoraleae drop pill in qualitative difference, according to 1: 3 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, beta-schardinger dextrin-, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 2.
Test 3: for observe drug extract and different substrates when 1: 9 the proportioning prepared Fructus Psoraleae drop pill in qualitative difference, according to 1: 9 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, beta-schardinger dextrin-, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 3.
Second group: the test of mixed-matrix
1. raw material: it is standby to make the dry powder that contains Chinese medicine Fructus Psoraleae active pharmaceutical ingredient in advance according to preparation method 1;
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate, molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether, molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 beta-schardinger dextrin----English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the Fructus Psoraleae drop pill of different size.
[result of the test]
Test 4: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 4.
Test 5: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 5.
Test 6: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 6.
Test 7: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 7.
Test 8: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 8.
Test 9: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 9.
Test 10: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 10.
Test 11: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 11.
Test 12: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Fructus Psoraleae drop pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as beta-schardinger dextrin-respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 12.
The group practices of table 1 drug extract and single-matrix
(drug extract: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 50.0 | 65 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 50.0 | 64 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 50.0 | 74 | ＜30 | ＞10 | + |
| Polyethylene Glycol 6000 | 50.0 | 73 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 8000 | 50.0 | 74 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 10000 | 50.0 | 76 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 20000 | 50.0 | 79 | ＜30 | ＞10 | ++ |
| Polyoxyethylene stearate 40 esters | 50.0 | 80 | ＜30 | ＞10 | ++ |
| Beta-schardinger dextrin- | 50.0 | 74 | ＜30 | ＞10 | + |
| Poloxamer | 50.0 | 78 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium | 50.0 | 70 | ＜30 | ＞10 | + |
| Sodium lauryl sulphate | 50.0 | 73 | ＞30 | ＞10 | + |
| Stearic acid | 50.0 | 62 | ＞30 | ＞10 | ++ |
| Sodium stearate | 50.0 | 64 | ＞30 | ＞10 | ++ |
| Glycerin gelatine | 50.0 | 61 | ＞30 | ＞10 | + |
| Lac | 50.0 | 63 | ＞30 | ＞10 | + |
The group practices of table 2 drug extract and single-matrix
(drug extract: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 25.0 | 68 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 25.0 | 84 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 25.0 | 86 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 25.0 | 88 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 8000 | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 25.0 | 91 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 25.0 | 90 | ＜30 | ＜10 | ++ |
| Beta-schardinger dextrin- | 25.0 | 82 | ＜30 | ＞10 | ++ |
| Poloxamer | 25.0 | 88 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium | 25.0 | 87 | ＜30 | ＞10 | +++ |
| Sodium lauryl sulphate | 25.0 | 76 | ＜30 | ＞10 | ++ |
| Stearic acid | 25.0 | 74 | ＞30 | ＞10 | +++ |
| Sodium stearate | 25.0 | 73 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 25.0 | 70 | ＞30 | ＞10 | +++ |
| Lac | 25.0 | 72 | ＞30 | ＞10 | +++ |
The group practices of table 3 drug extract and single-matrix
(drug extract: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 10.0 | 73 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 10.0 | 81 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 10.0 | 88 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 8000 | 10.0 | 91 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 10.0 | 92 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 10.0 | 91 | ＜30 | ＜10 | ++ |
| Beta-schardinger dextrin- | 10.0 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer | 10.0 | 86 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium | 10.0 | 84 | ＜30 | ＞10 | +++ |
| Sodium lauryl sulphate | 10.0 | 78 | ＜30 | ＞10 | +++ |
| Stearic acid | 10.0 | 75 | ＞30 | ＞10 | +++ |
| Sodium stearate | 10.0 | 76 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 10.0 | 73 | ＞30 | ＞10 | +++ |
| Lac | 10.0 | 75 | ＞30 | ＞10 | +++ |
The group practices of table 4 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 50 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 50 | 83 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 50 | 80 | ＜30 | ＞10 | ++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 1 | 50 | 76 | ＜30 | ＞10 | + |
The group practices of table 5 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 25 | 89 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 25 | 87 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 25 | 84 | ＜30 | ＞10 | ++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 1 | 25 | 85 | ＜30 | ＞10 | ++ |
The group practices of table 6 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 10 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 10 | 88 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 1 | 10 | 89 | ＜30 | ＞10 | +++ |
The group practices of table 7 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 50 | 89 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 5 | 50 | 90 | ＜30 | ＜10 | ++ |
The group practices of table 8 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 25 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 25 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 25 | 91 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 5 | 25 | 90 | ＜30 | ＜10 | +++ |
The group practices of table 9 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 10 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 10 | 90 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 5 | 10 | 89 | ＜30 | ＜10 | +++ |
The group practices of table 10 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 50 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 50 | 87 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 10 | 50 | 89 | ＜30 | ＞10 | +++ |
The group practices of table 11 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 25 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 25 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 25 | 89 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 10 | 25 | 87 | ＜30 | ＜10 | +++ |
The group practices of table 12 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Beta-schardinger dextrin-: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
1. can be seen by the result in the table: when the ratio of drug extract and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all undesirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of drug extract and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of drug extract and substrate is 1: 9, the rounding rate, the ball method of double differences is different and index such as hardness improves not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly becomes
Claims (2)
1. one kind is used for the treatment of vitiligo, psoriatic Fructus Psoraleae drop pill, is raw material with the extract that contains the Fructus Psoraleae effective ingredient, is prepared from the pharmaceutically suitable carrier as substrate, it is characterized in that:
(1) gets Fructus Psoraleae coarse powder 500g, according to percolation under 2000 editions Pharmacopoeia of People's Republic of China appendix IO fluid extracts and the extractum item, make solvent with 75% ethanol, flood after 48 hours slowly percolation, collect percolate 2500ml, filter, at 60 ℃, being decompressed to and being concentrated into relative density under the 0.1MPa condition is 1.05～1.15 thick paste, or continue to make drying under the same conditions, be ground into dry powder, promptly get the extract that contains the Fructus Psoraleae effective ingredient, standby;
(2) described substrate is the mixture of cetomacrogol 1000～Macrogol 2000 0 and polyoxyethylene stearate 40 esters or carboxymethyl starch sodium, by weight, its mixed proportion is that the mixed proportion of polyoxyethylene stearate 40 esters or carboxymethyl starch sodium and cetomacrogol 1000～Macrogol 2000 0 is 1: 1～1: 10, and the ratio of described extract and substrate is 1: 3;
(3) according to aforementioned proportion, accurately take by weighing drug extract and substrate, be placed in the heating container heating while stirring, standby until the fused solution that obtains containing drug extract and substrate or emulsion or suspension;
(4) temperature control system of adjustment drop pill machine makes the water dropper heating of drop pill machine and maintains the temperature at 50 ℃～90 ℃, and the condensing agent cooling also maintains the temperature at 40 ℃～-5 ℃;
When (5) temperature for the treatment of dropping-pill machine head and condensing agent reaches desired state of temperature respectively, will contain the fused solution of drug extract and substrate or emulsion or suspension and place in the water dropper jar of drop pill machine, splash in the condensing agent, shrink molding promptly.
2. Fructus Psoraleae drop pill as claimed in claim 1 is characterized in that: described condensing agent be methyl-silicone oil or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100634686A CN100382783C (en) | 2005-04-11 | 2005-04-11 | Psoralea drip pill an dits preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100634686A CN100382783C (en) | 2005-04-11 | 2005-04-11 | Psoralea drip pill an dits preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686386A CN1686386A (en) | 2005-10-26 |
| CN100382783C true CN100382783C (en) | 2008-04-23 |
Family
ID=35304428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100634686A Expired - Fee Related CN100382783C (en) | 2005-04-11 | 2005-04-11 | Psoralea drip pill an dits preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100382783C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294923A (en) * | 1999-11-03 | 2001-05-16 | 广东省中医院 | Nose drop of Fructus Psoraleae and its production process |
| CN1543945A (en) * | 2004-03-24 | 2004-11-10 | 吉林省中医中药研究院 | Medicine and technique for monomer extraction from psoralea fruit |
-
2005
- 2005-04-11 CN CNB2005100634686A patent/CN100382783C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294923A (en) * | 1999-11-03 | 2001-05-16 | 广东省中医院 | Nose drop of Fructus Psoraleae and its production process |
| CN1543945A (en) * | 2004-03-24 | 2004-11-10 | 吉林省中医中药研究院 | Medicine and technique for monomer extraction from psoralea fruit |
Non-Patent Citations (4)
| Title |
|---|
| 不同制备方法对补骨脂酊含量的影响. 郭代红等.中药材，第18卷第4期. 1995 * |
| 中华人民共和国卫生部药品标准中药成方制剂. 卫生部药典委员会，127，卫生部药典委员会. 1998 * |
| 固体分散技术大滴丸极具发展前景的现代中药制剂. 曲韵智.医药经济报. 2004 * |
| 补骨脂的化学成分及药理作用研究进展. 吕娟等.沈阳药科大学学报，第13卷第3期. 1996 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686386A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382784C (en) | Danhong drip pill prepared from salvia root and carthamus and its preparation method | |
| CN100358506C (en) | Compound musk drip pill and its preparation method | |
| CN100427068C (en) | Kangai drip pill for treating tumour, hepatitis B and its preparation method | |
| CN100348170C (en) | Yitongshu drop pill for treating pain and its preparation method | |
| CN1315463C (en) | Guanxinning drip pill for treating heart disease and its preparation method | |
| CN100382783C (en) | Psoralea drip pill an dits preparation method | |
| CN1322854C (en) | Cold drop pills of mulberry and ginger in use for eliminating draft, clearing away heat, and preparing method | |
| CN100375630C (en) | Compound drop pills with flavescent sophora root and its preparation method | |
| CN1315464C (en) | Wild aconite drip pill for treating cancer pain and its preparation method | |
| CN100348169C (en) | Saussurea involucrata drop pill and its preparation method | |
| CN100453072C (en) | Isatis root drops and preparation thereof | |
| CN100364505C (en) | Fengshining drop pill for treating rheumatism and its preparation method | |
| CN1315472C (en) | Motherwort dropping pill and its preparing method | |
| CN100427070C (en) | Dripping pills for treating all kinds of rhinitis and its preparation method | |
| CN100348175C (en) | Bistort drop pill and preparation method | |
| CN100358562C (en) | Tendril-leaved fritillary bulb loquat drop pills and preparation method thereof | |
| CN100542515C (en) | Milkwort root pill and preparation method thereof | |
| CN100348177C (en) | Two kinds of oral drip pills for treating tracheitis and its preparation method | |
| CN100367937C (en) | Throat dripping pill for clearing away heat and toxic material and its preparing method | |
| CN100358496C (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN100358500C (en) | Fleabane and earthworm dripping pill and its preparing method | |
| CN100427069C (en) | Tongkening drip pill used for assistant treating of tumour and its preparation method | |
| CN1332669C (en) | Dripping pills for reducing swelling and easing pain and its preparing method | |
| CN100542519C (en) | It with the Flos lupuli extractum pulmonary-toxin-clearing dropping pill of raw material and preparation method thereof | |
| CN100375613C (en) | Schizandrol dripping pills for decreasing aminopherase and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080423 |